Prepare for up to a Dozen Humira Biosimilars

November 2022

Up to 12 biosimilars for Humira (adalimumab) are slated to hit the market in 2023...starting with Amjevita in January.

This is a big deal. Humira is approved for many conditions...such as rheumatoid arthritis, plaque psoriasis, and Crohn’s disease.

Plus this injectable biologic is a top seller...annual revenue is over $20 billion.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Emergency Preparedness Be Ready to Navigate Med Issues During a Disaster or Emergency
Biosimilars Prepare for up to a Dozen Humira Biosimilars
Influenza Limit Mishaps With Antiviral Meds for Flu
Contraceptives Elevate Your Understanding of Emergency Contraception
Controlled Substances Prevent, Detect, and Respond to Internal Diversion
Anticoagulants Use Strategies to Improve Safety With Warfarin
Needles & Syringes Point Out Differences Among Pen Needles
Heart Failure Stay Alert for Meds That Can Exacerbate Heart Failure
Hormone Therapy Minimize Mix-Ups With Menopausal Hormone Therapy